120926-60-5Relevant articles and documents
A minimalistic approach to identify substrate binding features in B1 Metallo-β-lactamases
Poeylaut-Palena, Andres A.,Tomatis, Pablo E.,Karsisiotis, Andreas I.,Damblon, Christian,Mata, Ernesto G.,Vila, Alejandro J.
, p. 5171 - 5174 (2007)
The 2-oxoazetidinylacetate sodium salt was synthesized as a model of a minimal β-lactam drug. This compound and the monobactam aztreonam were assayed as substrates of the Metallo-β-lactamase BcII. None of them was hydrolyzed by the enzyme. While the azeti
DRUGS TO TREAT OCULAR DISORDERS
-
Page/Page column 205-206, (2019/11/12)
The present invention provides new prodrugs of therapeutically active loop diuretics, including oligomeric prodrugs, and compositions to treat medical disorders, for example, ocular disorders such as glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.
NOVEL COMPOUNDS
-
, (2016/02/26)
A compound of formula (I) or a pharmaceutically acceptable derivative thereof, (formula 1) wherein R1,R2, R3, R4, R5, X, m and n are defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.
